Država: Izrael
Jezik: angleščina
Source: Ministry of Health
WARFARIN SODIUM
TARO PHARMACEUTICAL INDUSTRIES LTD
B01AA03
TABLETS
WARFARIN SODIUM 6 MG
PER OS
Required
TARO PHARMACEUTICAL INDUSTRIES LTD
WARFARIN
WARFARIN
Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolis. Coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
2023-06-30
Final Physician Leaflet 08.2020 1 PRESCRIBING INFORMATION COUMADIN TABLETS 1. NAME OF THE MEDICINAL PRODUCT COUMADIN 1 mg COUMADIN 2 mg COUMADIN 2.5 mg COUMADIN 5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet of Coumadin 1 mg contains 1 mg warfarin sodium. Each tablet of Coumadin 2 mg contains 2 mg warfarin sodium. Each tablet of Coumadin 2.5 mg contains 2.5 mg warfarin sodium. Each tablet of Coumadin 5 mg contains 5 mg warfarin sodium. For excipients, see 6.1. 3. PHARMACEUTICAL FORM Tablets. Presentation: COUMADIN 1 mg tablets are pink, flat capsule shaped, beveled tablets, one side engraved with “WARFARIN” and "TARO", and other side scored and engraved with “1”. COUMADIN 2 mg tablets are lavender, flat capsule shaped, beveled tablets, one side engraved with “WARFARIN” and "TARO", and other side scored and engraved with “2”. COUMADIN 2.5 mg tablets are green, flat capsule shaped, beveled tablets, one side engraved with “WARFARIN” and "TARO", and other side scored and engraved with “2½”. COUMADIN 5 mg tablets are peach, flat capsule shaped, beveled tablets, one side engraved with “WARFARIN” and "TARO", and other side scored and engraved with “5”. The tablet can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS COUMADIN is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. COUMADIN is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. COUMADIN is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Final Physician Leaflet 08.2020 2 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage and administration of COUMADIN must be individualized for each patient according to the particular patient's PT/INR response to the drug. The dosage should be adjusted based upon the pat Preberite celoten dokument